Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region.
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. De Giorgi U, et al. Among authors: penson d. Eur J Cancer. 2021 Dec;159:237-246. doi: 10.1016/j.ejca.2021.10.015. Epub 2021 Nov 14. Eur J Cancer. 2021. PMID: 34784577 Free article. Clinical Trial.
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Kantoff PW, et al. Among authors: penson df. N Engl J Med. 2010 Jul 29;363(5):411-22. doi: 10.1056/NEJMoa1001294. N Engl J Med. 2010. PMID: 20818862 Free article. Clinical Trial.
Castration-resistant prostate cancer: AUA Guideline.
Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, Lin DW, Lowrance WT, Murad MH, Oh WK, Penson DF, Kibel AS. Cookson MS, et al. J Urol. 2013 Aug;190(2):429-38. doi: 10.1016/j.juro.2013.05.005. Epub 2013 May 9. J Urol. 2013. PMID: 23665272
Adverse effects of androgen deprivation therapy and strategies to mitigate them.
Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Nguyen PL, et al. Among authors: d amico av, penson df. Eur Urol. 2015 May;67(5):825-36. doi: 10.1016/j.eururo.2014.07.010. Epub 2014 Aug 2. Eur Urol. 2015. PMID: 25097095 Review.
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach.
Morgans AK, van Bommel AC, Stowell C, Abrahm JL, Basch E, Bekelman JE, Berry DL, Bossi A, Davis ID, de Reijke TM, Denis LJ, Evans SM, Fleshner NE, George DJ, Kiefert J, Lin DW, Matthew AG, McDermott R, Payne H, Roos IA, Schrag D, Steuber T, Tombal B, van Basten JP, van der Hoeven JJ, Penson DF; Advanced Prostate Cancer Working Group of the International Consortium for Health Outcomes Measurement. Morgans AK, et al. Among authors: penson df. Eur Urol. 2015 Nov;68(5):891-8. doi: 10.1016/j.eururo.2015.06.007. Epub 2015 Jun 28. Eur Urol. 2015. PMID: 26129856 Free article.
Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.
Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF. Flanders SC, et al. Among authors: penson df. Future Oncol. 2018 Mar;14(6):527-536. doi: 10.2217/fon-2017-0438. Epub 2018 Feb 8. Future Oncol. 2018. PMID: 29417827 Free PMC article.
635 results